Navigation Links
New mouse model confirms how type 2 diabetes develops
Date:5/3/2013

Researchers at Lund University in Sweden have developed a new mouse model that answers the question of what actually happens in the body when type 2 diabetes develops and how the body responds to drug treatment. Long-term studies of the middle-aged mouse model will be better than previous studies at confirming how drugs for type 2 diabetes function in humans.

"The animal models for type 2 diabetes studies that have previously existed have not been optimal because they use young mice. Our idea was to create a model that resembles the situation in the development of type 2 diabetes in humans. We generally get the disease in middle age when we start to put on weight and live a more sedentary, and more stressful, life. Our new middle-aged mouse model has enabled us to study long-term physiological effects of the development and treatment of type 2 diabetes in a completely new way", said Bilal Omar, one of the researchers behind the study.

What the Lund researchers have done is to feed normal mice fatty food over a long period from the age of eight months, i.e. middle age, until the end of their natural lives at the age of two. The mice become overweight, and develop high blood sugar levels and reduced insulin release, as expected before the onset of type 2 diabetes.

"Throughout the period we were able to study the process that leads to the development of type 2 diabetes with a lifestyle like that of people predisposed to the condition", said Bilal Omar.

In the study, the researchers could confirm that fatty foods lead to inflammation in the islets of Langerhans in the pancreas, which produce insulin. Researchers have seen inflammation in the islets in people with type 2 diabetes, but in Bilal Omar's view, it is only with the new mouse model that it can really be confirmed. Inflammation in these islets is an important risk factor for type 2 diabetes.

"What was so interesting and exciting was that the mice that were treated with DPP-4 inhibitors, a class of drugs used for type 2 diabetes, did not develop inflammation and they maintained good insulin production. They were still obese, but had normal blood sugar, were otherwise healthy and lived longer", said Bilal Omar.

Researchers have worked for decades and on many fronts to understand the causes and course of diabetes. Models of different diseases are therefore an important tool for the development of new and better drugs, and a requirement to develop the best possible drugs is to understand what is happening on a physiological level.

"The goal is to design drugs and treatments which, if they can't cure the disease, can at least give the patient a better quality of life for several years", said Bilal Omar.

"Another aspect of our findings is that the inflammation in the islets was caused by a high-fat diet. Even if it is too early to draw parallels with the diet of humans, it makes it doubtful whether a high-fat diet over a long period should be recommended, as in the LCHF diet", said Professor Bo Ahrn, another of the researchers behind the study.


'/>"/>

Contact: Bilal Omar
46-462-220-760
Lund University
Source:Eurekalert

Related medicine news :

1. Transparent Mouse Brain Could Shed Light on Human Brain Health
2. Bitter melon juice prevents pancreatic cancer in mouse models
3. Mouse model improves understanding of clear cell sarcoma
4. Mouse menopause model sheds light on UTIs in post-menopausal women
5. Mouse Study Offers Clues to Obesity-Diabetes Link
6. Bright Light at Night Could Up Depression Risk, Mouse Study Suggests
7. New, improved mouse model of human Alzheimers may enable drug discovery
8. Mouse model exposes a new type of T cell to target melanoma
9. A CNIO team creates a unique mouse model for the study of aplastic anaemia
10. Mouse With Human-Like Immune System Could Advance AIDS Research
11. Scientists develop mouse model that could lead to new therapies for liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is a ... FASCP. The program was recently launched on March 1, and Dr. Wentz discussed ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
Breaking Medicine Technology: